Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR1459 tablets for primary membranous nephropathy
CTR20211976Phase 2Active
- Sponsor
- Reistone Biopharma
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of edralbrutinib in idiopathic membranous glomerulonephritis (IMG), sponsored by Reistone Biopharma. Started Dec 2021; status: active.
02
Drugs
edralbrutinib
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20211976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211976.